Malignant Brain Astrocytomas: Extent of Resection Affects Survival
Malignant astrocytomas, which include anaplastic astrocytomas and glioblastomas (GBM) are the most common malignant primary central nervous system tumors in adults. Despite advances in medical and surgical therapy, the median survival for patients harboring these tumors remains less than 2 years. This shortened survival has made many wonder if aggressive surgical resection prolongs survival for patients with malignant astrocytomas. For many solid organ malignant tumors, gross total resection with clear margins is associated with extended survival. However, the effect of extensive resection on prolonging survival for patients with malignant astrocytomas is less clear. This lack of clarity is confounded by the fact that these tumors are frequently invasive and widely infiltrative, and often involve eloquent areas. Aggressive surgery therefore may be associated with new deficits. This chapter evaluates the role that aggressive resection has on survival for patients with malignant astrocytomas.
KeywordsMalignant Glioma Anaplastic Astrocytoma Gross Total Resection Extensive Resection Malignant Astrocytoma
- Grant R, Metcalfe SE (2005) Biopsy versus resection for malignant glioma. Cochrane Database Syst Rev 2:CD002034Google Scholar
- Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:190–198PubMedCrossRefGoogle Scholar
- Laws ER, Parney IF, Huang W, Anderson F, Morris AM, Asher A, Lillehei KO, Bernstein M, Brem H, Sloan A, Berger MS, Chang S (2003) Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg 99:467–473PubMedCrossRefGoogle Scholar
- Levin VA, Yung WK, Bruner J, Kyritsis A, Leeds N, Gleason MJ, Hess KR, Meyers CA, Ictech SA, Chang E, Maor MH (2002) Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas. Int J Radiat Oncol Biol Phys 53:58–66PubMedCrossRefGoogle Scholar